InhaleRx Limited (AU:IRX) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited has received ethics approval to commence Phase 2 clinical trials for IRX-211, an innovative non-opioid treatment for breakthrough cancer pain. This development marks a significant milestone in offering a safer alternative to traditional opioid-based treatments, which carry risks of dependency and adverse side effects. With a market potential exceeding USD 1 billion, IRX-211 aims to transform pain management for cancer patients worldwide.
For further insights into AU:IRX stock, check out TipRanks’ Stock Analysis page.